Fresh analysis reveals that individuals who come off blockbuster slimming jabs like semaglutide or tirzepatide may regain reduced body mass at a significantly accelerated pace than those who end conventional lifestyle plans.
Research printed in a prominent medical journal shows that while obese people often shed a large proportion of their body weight while undergoing treatment, the weight comes back at an average rate of 0.8 kg per month upon discontinuation.
"Users buying these treatments should be cognizant of the danger of rapid rebound weight gain when the therapy is stopped," cautioned lead investigator Dr. Susan Jebb.
That rate of regain implies a reversion to pre-treatment weight in about a year and a half.
Analyzing Treatments
The research, which looked at 37 of trials involving thousands of participants, compared the results of these new drugs with older methods.
Scientists emphasize that individuals who lose weight through dieting typically see a less rapid creep back—around 0.1 kg a month—post-intervention.
The Reason for the Fast Rebound
Nutrition scientists propose the way of the drugs accounts for the heightened regain.
GLP-1 drugs copy a natural hormone called GLP-1, which helps regulate feelings of fullness.
"Sustained high doses of GLP-1 concentrations far above than the body's typical production might result in the body to generate a reduced amount of its endogenous hormone, and could reduce sensitivity to its effects," said Dr. Adam Collins, a nutrition expert.
"Stopping of this hormone supplement leads to appetite is no longer kept in check, making overeating a significant risk."
A Lifelong Disease?
Medical guidelines recommend the jabs for individuals with obesity-related medical conditions, accompanied by prescribed diet and exercise modifications.
Professionals argue that, due to the significant potential of weight regain, the therapy might need to be long-term.
This perspective is supported by drug manufacturers, who state that the results "emphasize the long-term nature of obesity," similar to managing diseases like diabetes.
Patient Accounts
People who have come off the medication describe a intense return of hunger.
"I experienced a switch that goes on and you're instantly starving," described an individual.
This challenge is exacerbated if patients have not adopted sustainable lifestyle or habit changes during therapy.
Widespread Interest
Figures suggest that millions of people in the UK have used these injections in the past year, with interest being substantial.
- Adoption is more common among women compared to men.
- The middle-aged age group shows the greatest level of interest.
- Many access the medications through private healthcare rather than the NHS.
Finally, researchers emphasize that while the jabs are effective tools for shedding pounds, they are not a standalone solution and long-term success likely depends on combined behavioural management.
